louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06719752: Assessing the Acute Effects of Diagonal Mobilization
Official title: ASSESSING the ACUTE EFFECTS of DIAGONAL MOBILIZATION on STATIC and DYNAMIC BALANCE in YOUNG FOOTBALL PLAYERS: a RANDOMIZED DOUBLE-BLIND STUDY
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: NA
Conditions: Aged 14 to 16
Play Football Regularly
Keywords: soccer
musculoskeletal manipulations
postural balance
biomechanics
Lead sponsor: Medical University of Gdansk
Sponsor class: OTHER
First posted: 2024-12-06
Enrollment: 50
Sex: ALL
Minimum age (years): 14
Maximum age (years): 16
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: Investigating the acute effects of mobilization on these parameters offers innovative insights for the practitioner community and sheds light on the strategy's potential effectiveness in mitigating injury risk. Therefore, this study aims to assess the immediate effects of mobilization on static and dynamic balance in young male and female soccer players using a randomized, double-blinded study design.

Detailed description: Participants underwent assessment twice: once before the intervention and again afterward. Tests included the single leg lend and hold test and the single leg standing test, measured using force plates.

Eligibility criteria: Inclusion Criteria:

* age between 14 to 16 years old, with regular soccer practice;
* absence of lower limb and lumbar spine surgery or injuries within the last 6 months (hip, knee, ankle), no current pain in the hip, knee, or ankle joints, no hypermobility of the lower limb joints, and no history of neurological or connective tissue disorders;
* availability for both assessment time points

Exclusion Criteria:

-

Primary outcomes:
measure: Single leg standing
timeFrame: 2-3 seconds
Secondary outcomes:
Other outcomes:
Locations:
city: Gdańsk
country: Poland
facility: AZS Central Academic Sports Center in Gdańsk
Study officials:
References:
Clinical trial NCT01778452: Endometrial Genomic Profile in Endometrial Priming
Official title: Profile Study of Genomics Endometrial Expression After Gonadotropin-releasing Hormone Agonist Administration and GnRH in Endometrial Priming.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Genomic Human Endometrial Expression Profile
Keywords: Endometrial priming, genomic expression. Natural cycle. Antagonist GnRH.
Lead sponsor: Instituto Valenciano de Infertilidad, IVI VALENCIA
Sponsor class: OTHER
Collaborators: name: Igenomix
First posted: 2013-01-29
Enrollment: 6
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: The aim of this study is to analyse genomics profile expression in endometrium under different endometrial priming for recipients.

Detailed description: We analyze the genomic profile of egg donors in different endometrial priming protocols, compared with natural cycle, including the conventional single long acting GnRH agonist injection in the mid luteal phase of the previous cycle of the endometrial priming and the single daily antagonist injection (Cetrorelix 0.25 mg) administered in the early follicular phase followed by endometrial priming. Endometrial biopsy will be taken in luteinizing hormone

* 7 or with P4 +5 in cases with endometrial priming with oestrogens therapy.

Eligibility criteria: Inclusion Criteria:

* 6 egg healthy volunteer egg donors.
* Volunteers.
* 18-35 years old
* Healthy.
* BMI \<28.

Exclusion Criteria:

* - BMI \> 28
* Smokers-

Primary outcomes:
measure: genetic endometrial human profile expression
timeFrame: Oocyte donors will be followed up for four to six months
Secondary outcomes:
Other outcomes:
Locations:
city: Valencia
country: Spain
facility: Ivi Valencia
Study officials:
affiliation: IVI Valencia
name: Carmen Vidal, MDphD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00613652: A Phase I, Dose-Escalation Study to Assess the Safety and Drug Levels in Blood of AZD4877 in Japanese Adult Patients
Official title: A Phase I, Open-Label, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 Administered Weekly in Japanese Adult Patients With Advanced Solid Malignancies
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Cancer
Tumors
Carcinoma
Keywords: solid tumors
solid malignancies
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2008-02-13
Enrollment: 30
Sex: ALL
Minimum age (years): 20
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The primary purpose of this study is to evaluate the safety and tolerability of AZD4877 on a weekly schedule in Japanese patients with advanced solid malignancies


Eligibility criteria: Inclusion Criteria:

* Patients diagnosed with solid tumour but which have no standard treatment or did not respond to previous treatments.
* Patients who usually have mild symptoms capable of walking and light and sedentary work.
* Patients who can stay in hospital at least during 4 weeks.

Exclusion Criteria:

* Patients who have received treatment with anti-cancer agent within 4 weeks prior to first dose of study treatment; 6 weeks if the anti-cancer agent is mitomycin.
* Patients with abnormally low levels of neutrophil count, platelet count, or haemoglobin, indicators of bone marrow function.
* Patients who received therapeutic radiotherapy at central nervous system within 3 months prior to first dose of study treatment; the other sites within 4 weeks; or local site within 2 weeks.

Primary outcomes:
measure: To evaluate the safety and tolerability of AZD4877 on a weekly schedule in Japanese patients with advanced solid malignancies
timeFrame: weekly
Secondary outcomes:
measure: To determine the PK profile of AZD4877 on a weekly schedule in Japanese patients with advanced solid malignancies
timeFrame: weekly
Other outcomes:
Locations:
city: Fukuoka
country: Japan
facility: Research Site
Study officials:
References:
Clinical trial NCT06981052: Prospective Evaluation of an Endoscopic Ultrasound (EUS)-Based Artificial Intelligence to Assist in the Deployment of Lumen Apposing Metal Stents for Gallbladder Drainage
Official title: Prospective Evaluation of an Endoscopic Ultrasound (EUS)-Based Artificial Intelligence to Assist in the Deployment of Lumen Apposing Metal Stents for Gallbladder Drainage
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Cholecystitis
Lead sponsor: University of Massachusetts, Worcester
Sponsor class: OTHER
First posted: 2025-05-20
Enrollment: 125
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients undergoing endoscopic ultrasound who have a gallbladder present

Brief summary: Lumen apposing metal stents are now being used to help patients who suffer from cholecystitis (infection of the gallbladder), especially in cases where patients are not candidates for surgery. Lumen apposing metal stents are effective for draining the gallbladder, however, placement is technically challenging. Scientists have developed an artificial intelligence to aid doctors in the deployment of these stents into the gallbladder. The aim of this study is test the performance of an artificial intelligence in providing physicians accurate information for gallbladder drainage.


Eligibility criteria: Inclusion Criteria:

* Age ≥ 18 years old
* Anticipation that patient may undergo endoscopic ultrasound
* Gallbladder present

Exclusion Criteria:

* Cholecystectomy
* No indication for endoscopic ultrasound

Primary outcomes:
measure: Accuracy of the EUS AI system in providing a recommendation (i.e. whether it is safe or not to drain the gallbladder)
timeFrame: Day 1
Secondary outcomes:
Other outcomes:
Locations:
city: Worcester
country: United States
facility: UMass Chan Medical School/Umass Memorial Health Care
state: Massachusetts
Study officials:
References:
Clinical trial NCT03864952: Infectious Agents Exposure : Archiving in Dental Plaque
Official title: Dental Plaque and Infectious Agents Story)
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Infection
Dental Calculus
Keywords: Infection
genomic
dental calculus
Lead sponsor: University Hospital, Brest
Sponsor class: OTHER
First posted: 2019-03-06
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients reffering to the Hospital university of Brest (France) 3 to 12 months before the study

Brief summary: We are studying the possibility of using dental calculus as a reservoir for the genes of an infectious agent that has infected the patient in previous months; as it is done to highlight climate change in ice samples.

Detailed description: From a sample of people who have had a microbiologically well-documented infection, we will study the possibility after genomic amplification to find, three to 12 months after genetic sequences of the infectious agent in the dental calculus of the person. The people will be recruited according to a large panel of infectious agent (gram + and gram bacterium, mycobacteria, parasite, fungus, DNA, RNA or retrovirus) and, of course, the presence of dental calculus.

Eligibility criteria: Inclusion Criteria:

* three months before, having been infected with a documented pathogen
* this infection must have been clinically obvious
* the patient must have dental calculus

Exclusion Criteria:

* to be under 18 years old
* to be incapable to consenting
* a tartar removal since the infection

Primary outcomes:
measure: successful detection of pathogen
timeFrame: 3 to 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Brest
country: France
facility: CHRU de Brest
Study officials:
affiliation: University Hopsital of Brest
name: Luc de Saint-Martin, MD, Ph
role: STUDY_DIRECTOR
References:
Clinical trial NCT02847052: Study of the Role of Soluble Inhibitor of Interleukin 22, Interleukin 22 Binding Protein (IL-22BP), in Chronic Inflammatory Bowel Disease
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Inflammatory Bowel Disease
Lead sponsor: Nantes University Hospital
Sponsor class: OTHER
First posted: 2016-07-27
Enrollment: 52
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Inflammatory bowel disease, Retrospective, controlled, open, monocentric study

Brief summary: IL-22 is an IL-10 family cytokine that plays major actions to increase intestinal epithelial barrier function and regeneration during experimental colitis. IL-22 binding protein is a small, soluble, and secreted protein potently inhibiting IL-22 actions through preventing the binding with IL-22 Recepteur. This study aims at characterizing how IL-22 binding protein is regulated in Inflammatory bowel disease to better understand the way IL-22 acts on epithelial cells during flares of the disease.


Eligibility criteria: Inclusion criteria

1. Crohn's disease or Ulcerative colitis
2. Healthy controls paired for age and sex
3. Samples availability in the biobank
4. Signed consent
5. No (Immune Mediated Inflammatory Disorders other than Inflammatory bowel disease
6. No other conditions predicted or known to affect IL-22/IL-22 recepteur /IL-22 binding protein regulation
7. Availability of clinical data
8. Age \>18 y.o.
9. No pregnancy

Primary outcomes:
measure: Regulation of Interleukine 22 binding protein expression in Crohn's disease or Ulcerative colitis
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Nantes University Hospital
name: Jérome Martin
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06074952: Comparing the Color Stability of Acrylic Denture Teeth in Different Staining Solutions
Official title: Comparing the Color Stability of Acrylic Denture Teeth in Different Staining Solutions-In Vitro Experimental Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Color Stability
Lead sponsor: Altamash Institute of Dental Medicine
Sponsor class: OTHER
First posted: 2023-10-10
Enrollment: 150
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: OTHER

Brief summary: The purpose of this (In Vitro Experimental Trial) is to assess (the color stability of acrylic denture teeth) in( different staining solutions) at (time intervals).

The (acrylic denture) teeth will be immersed in (staining solutions) and the values will be recorded at (different time intervals).

Three groups will be made:

* Group A- Control group
* Group B- Study group
* Group C- Study group

Detailed description: In this study, two brands of acrylic denture teeth will be used for comparing the color stability in different staining solutions at time intervals. Identified staining substances which are tea, coke, and turmeric will be used for the staining effect evaluation. Honey solution will be used for the first time as a staining agent because honey consumption is most common in all the age groups due to its therapeutic effects. In this study, all the color values will be measured by using Portable Colorimeter (NH300, China).These values will be measured before the immersion and then after 7-days, 15-days and 21-days interval after the immersion in the solutions.

The purpose of this study is to assess the color stability of acrylic denture teeth in different staining solutions at time intervals.

Eligibility criteria: Inclusion Criteria:

1. Maxillary central incisor teeth
2. Teeth with normal flat labial surfaces
3. Inter-penetrating polymer network (IPN) teeth

Exclusion Criteria:

1. Posterior teeth
2. Teeth with stains
3. Fractured and worn-out teeth

Primary outcomes:
measure: Color stability
timeFrame: The acrylic teeth will be measured at 7-days, 15-days, and lastly at 21-days interval.
Secondary outcomes:
Other outcomes:
Locations:
city: Karachi
country: Pakistan
facility: Altamash Institute of Dental medicine and Karachi University
state: Sindh
Study officials:
affiliation: Altamash Institute of Dental Medicine
name: Naseer Ahmed, BDS,FCPS
role: STUDY_DIRECTOR
References:
Clinical trial NCT04311632: A Dose Escalation Study in de Novo Renal Transplantation
Official title: A 12-Month, Randomized, Controlled, Open-Label, Dose Escalation Study Evaluating Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of an Anti-CD2 Monoclonal Antibody, TCD601(Siplizumab) Compared to Anti-thymocyte Globulin (rATG), as Induction Therapy in de Novo Renal Transplant Recipients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Kidney Transplantation
Lead sponsor: ITB-Med LLC
Sponsor class: INDUSTRY
First posted: 2020-03-17
Enrollment: 13
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study is to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of escalating doses of TCD601 when compared to rATG in de novo renal transplant patients.


Eligibility criteria: Key Inclusion Criteria:

* Able to understand the study requirements and provide written informed consent before and study assessment is performed.
* Male or female patients ≥ 18 to 70 years of age.
* Recipients of a de novo renal allograft from a heart-beating deceased, living unrelated, or non-HLA identical living related donor.
* Recipients of a kidney with a cold ischemia time (CIT) less than 30 hours.

Key Exclusion Criteria:

* Multiple-organ transplant recipients
* Subjects who have received a kidney allograft previously
* Recipient of a kidney from an HLA identical living related donor
* Recipient of a kidney from a donor after cardiac death
* Subjects at high immunological risk for rejection

Primary outcomes:
measure: Number of Participants With Treatment-emergent Adverse Events as Assessed by CTCAE v5.0.
timeFrame: 12 months
measure: Measure Peak Plasma Concentration (Cmax) Over Time.
timeFrame: 12 months
measure: Measure the Area Under the Plasma Concentration Versus Time Curve (AUC).
timeFrame: 12 months
Secondary outcomes:
measure: The Incidence of Rejection at 12 Months Post-transplant.
timeFrame: 12 months
measure: To Assess the Change in Renal Function Over Time.
timeFrame: 12 months
Other outcomes:
Locations:
city: Atlanta
country: United States
facility: Emory University
state: Georgia
city: Kansas City
country: United States
facility: Kansas University Medical Center
state: Kansas
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
city: Livingston
country: United States
facility: Saint Barnabas Medical Center
state: New Jersey
Study officials:
affiliation: ITB-Med LLC
name: Nick Hryciw, MA
role: STUDY_DIRECTOR
References:
Clinical trial NCT01906632: Gene Expression Profiling of Malignant Tumor Predict the Therapeutic Response of DC-CIK Immunotherapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Malignant Tumor
Lead sponsor: Capital Medical University
Sponsor class: OTHER
First posted: 2013-07-24
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To investigate gene expression profile and immunological associated analysis relating to immunotherapy response of patients with malignant tumor after DC-CIK immunotherapy.

Detailed description: 1. The patients with malignant tumor are treated with dendritic cells (DC) plus cytokine induced killer cells (CIK) .
2. Venous blood (4 ml) is collected from each subject and placed into tubes containing Ethylene Diamine Tetraacetic Acid(EDTA) before and after each treatment. Lymphocytes are sorted by Fluorescence Activated Cell Sorting(FACS) and stored at -80°C until processing.
3. The T-Cell Receptor/B-Cell Receptor gene expression is detected by micro-array。
4. Estimate Immunotherapy response, time to disease progression, survival rates and clinical benefit response on patients. Response is assessed using Response Evaluation Criteria in Solid Tumor Group (RECIST) guidelines. Degree of response is used to divide the cancers into two groups: sensitive and non-sensitive to immunotherapy.
5. Compare the gene expression profile between different immunotherapy response groups to explore the mechanism that predict the DC-CIK immunotherapy response.

Eligibility criteria: Inclusion Criteria:

* histologically confirmed with malignant tumor;
* Age: 18-80 years;
* an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;
* At least one measurable lesion according to the RECIST criteria;
* Adequate bone marrow, cardiac, liver, and renal function;
* Life expectancy ≥2 months;
* Not received other anti-tumor treatment
* Informed consent signed

Exclusion Criteria:

* previous history of other malignancies;
* Uncontrolled central nervous system metastases;
* Serious or uncontrolled concurrent medical illness.

Primary outcomes:
measure: T-Cell Receptor/B-Cell Receptor gene expression
timeFrame: 3 month
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Capital Medical Unvierstiy Cancer Center/ Beijing Shijitan Hospital
Study officials:
References:
Clinical trial NCT02803632: Clinical and Actigraphic Profile of Young Patients Admitted for Attempted Suicide
Official title: Clinical and Actigraphic Profile of Young Patients Admitted for Attempted Suicide: Investigation of Disruptive Mood Dysregulation Disorder
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Suicide, Attempted
Keywords: young
disruptive mood dysregulation disorder
actigraphic profile
Lead sponsor: Centre Hospitalier Universitaire, Amiens
Sponsor class: OTHER
First posted: 2016-06-17
Enrollment: 98
Sex: ALL
Minimum age (years): 6
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: An excess suicide-related morbidity is observed among young people in the Picardie region, as reflected by the \> 100% occupation rate of the Amiens University Hospital Adolescent Medicine Unit

Detailed description: An excess suicide-related morbidity is observed among young people in the Picardie region, as reflected by the \> 100% occupation rate of the Amiens University Hospital Adolescent Medicine Unit. New approaches have been proposed to these problems that have led us to reorganize our diagnostic practices: 1) more precise characterization of suicidal behaviour by using standardized instruments such as the French version of the Columbia-Suicide Severity Rating Scale developed by Posner (C-SSRS); 2) new clinical entities, such as disruptive mood dysregulation disorder, are now proposed in international classifications (DSM 5 field trial); 3) investigations such as recording of the circadian rhythm of motor activity by actigraphy are being studied as a laboratory complement to psychiatric diagnosis.

Eligibility criteria: Inclusion Criteria:

* children/adolescents admitted after a suicide attempt

Exclusion Criteria:

* severe depression
* mental retardation
* pervasive developmental disorder
* active psychotic episode,
* drug and alcohol abuse at the time of admission
* organic sleep-wake disorders (sleep-related respiratory and motor disorders, narcolepsy)
* any contraindication formulated by the clinical team
* patients not covered by French national health insurance, patients deprived of their freedom as stipulated in Article L.1121-6 of the French Public Health Code

Primary outcomes:
measure: The variable absence / presence of the disruptive mood dysregulation disorder (DMDD)
timeFrame: Day 0
Secondary outcomes:
Other outcomes:
Locations:
city: Amiens
country: France
facility: CHU Amiens
city: Paris
country: France
facility: AP HP
Study officials:
affiliation: CHU Amiens
name: Jean-Marc GUILE, PhD
role: PRINCIPAL_INVESTIGATOR
References: